Proteins

Product Data Sheet

(R)-Elagolix

Cat. No.: HY-14789 CAS No.: 834153-87-6 Molecular Formula: $C_{32}H_{30}F_{5}N_{3}O_{5}$ Molecular Weight: 631.59

Target: **GnRH Receptor** Pathway: GPCR/G Protein

Storage: Powder -20°C 3 years

2 years

In solvent -80°C 2 years

> -20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 62.5 mg/mL (98.96 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.5833 mL	7.9165 mL	15.8331 mL
	5 mM	0.3167 mL	1.5833 mL	3.1666 mL
	10 mM	0.1583 mL	0.7917 mL	1.5833 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM). Target: GnRHin vitro: Elagolix is a short-acting, nonpeptide, GnRH antagonist, administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose-dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full suppression at higher doses. Elagolix is regarded as the frontrunner of a new class of GnRH inhibitors that have been denoted as second-generation, due to their non-peptide nature and oral bioavailability.

nsity. Reprod Sci. 2014 Nov;21(11):1341-1351.			
			edical applications. For research use only.	
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpress.com	
	Address: 1	Deer Park Dr, Suite Q, Monm	outh Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com